Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8644 · 1 trial · 2 indications
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
| Arm | Type | Description |
|---|---|---|
| MK-8644 | EXPERIMENTAL | Participants receive MK-8644 orally under fasted or fed conditions depending on randomization. |
| Placebo | PLACEBO_COMPARATOR | Participants receive matching placebo for MK-8644 orally under fasted or fed conditions depending on randomization. |
| Name | Type | Description |
|---|---|---|
| MK-8644 | DRUG | Oral administration |
| Placebo for MK-8644 | DRUG | Oral administration |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a BMI between 18 and 36 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically signific...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| AbbVie, Inc. | ABBV | 6 | PHASE3 | Risankizumab, ABBV-295 |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 5 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 5 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
| Amgen Inc. | AMGN | 1 | PHASE1 | Apremilast, Apremilast IR |
MK-8644 is an investigational small molecule being developed by Merck for psoriasis. It is in Phase 1 clinical development, and the only listed trial enrolls both healthy participants and participants with psoriasis to evaluate the drug in a placebo-controlled, double-blind, randomized setting.
MK-8644 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is running the Phase 1 program for the compound, including the trial listed as MK-8644-001 in Australia.
MK-8644 is in Phase 1 clinical development. It is an investigational small molecule for psoriasis and has not completed any trials in the listed program. One Phase 1 trial is currently recruiting, with a planned enrollment of 132 participants.
MK-8644 is being studied in trial NCT07850310, titled A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001). It is a recruiting Phase 1 trial in Australia with 132 planned participants, randomized, double-blind, and placebo-controlled, enrolling adults 18 years and older.
Yes, MK-8644 is a small molecule. It is an investigational oral-style small molecule drug in Phase 1 development at Merck for psoriasis, studied in a randomized, double-blind, placebo-controlled trial that includes both healthy volunteers and participants with psoriasis.